These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 37995040)
1. Safety and Efficacy of Cangrelor in Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis. Mostafa MR; Eid MM; Awad AK; Takla A; Hassan AR; Katamesh BE; AlBarakat MM; Ziada AR; Mohamed S; Al-Azizi KM; Goldsweig AM Am J Cardiovasc Drugs; 2024 Jan; 24(1):71-81. PubMed ID: 37995040 [TBL] [Abstract][Full Text] [Related]
2. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. Westman PC; Lipinski MJ; Torguson R; Waksman R Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL; JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566 [TBL] [Abstract][Full Text] [Related]
4. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. Cavender MA; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Lopes RD; Leonardi S; Deliargyris EN; Prats J; Mahaffey KW; White HD; Bhatt DL; Circ Cardiovasc Interv; 2022 Jan; 15(1):e010390. PubMed ID: 34915723 [TBL] [Abstract][Full Text] [Related]
5. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. Gutierrez JA; Harrington RA; Blankenship JC; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Généreux P; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL; Eur Heart J; 2016 Apr; 37(14):1122-30. PubMed ID: 26400827 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL JAMA Cardiol; 2017 Feb; 2(2):127-135. PubMed ID: 27902833 [TBL] [Abstract][Full Text] [Related]
7. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887 [TBL] [Abstract][Full Text] [Related]
8. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Sawlani NN; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL Circ Cardiovasc Interv; 2017 Jan; 10(1):. PubMed ID: 28039321 [TBL] [Abstract][Full Text] [Related]
9. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y Abtan J; Ducrocq G; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL Circ Cardiovasc Interv; 2019 Mar; 12(3):e007445. PubMed ID: 30871355 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis. Gan XD; Wei BZ; Fang D; Fang Q; Li KY; Ding SL; Peng S; Wan J Curr Med Res Opin; 2015 Dec; 31(12):2313-23. PubMed ID: 26402735 [TBL] [Abstract][Full Text] [Related]
11. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Steg PG; Bhatt DL; Hamm CW; Stone GW; Gibson CM; Mahaffey KW; Leonardi S; Liu T; Skerjanec S; Day JR; Iwaoka RS; Stuckey TD; Gogia HS; Gruberg L; French WJ; White HD; Harrington RA; Lancet; 2013 Dec; 382(9909):1981-92. PubMed ID: 24011551 [TBL] [Abstract][Full Text] [Related]
12. Cangrelor Use Patterns and Transition to Oral P2Y Rymer JA; Bhatt DL; Angiolillo DJ; Diaz M; Garratt KN; Waksman R; Edwards L; Tasissa G; Salahuddin K; El-Sabae H; Dell'Anna C; Davidson-Ray L; Washam JB; Ohman EM; Wang TY J Am Heart Assoc; 2022 Jun; 11(11):e024513. PubMed ID: 35621210 [TBL] [Abstract][Full Text] [Related]
14. Feasibility and safety of cangrelor in patients with suboptimal P2Y Selvarajah A; Tavenier AH; Bor WL; Houben V; Rasoul S; Kaplan E; Teeuwen K; Hofma SH; Lipsic E; Amoroso G; van Leeuwen MAH; Berg JMT; van 't Hof AWJ; Hermanides RS BMC Cardiovasc Disord; 2021 Jun; 21(1):292. PubMed ID: 34118880 [TBL] [Abstract][Full Text] [Related]
15. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341 [TBL] [Abstract][Full Text] [Related]
16. Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. Peterson BE; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Lopes RD; Leonardi S; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL Circ Cardiovasc Interv; 2022 Mar; 15(3):e011069. PubMed ID: 35196863 [TBL] [Abstract][Full Text] [Related]
17. Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. Tang XF; Fan JY; Meng J; Jin C; Yuan JQ; Yang YJ Atherosclerosis; 2014 Apr; 233(2):568-578. PubMed ID: 24534451 [TBL] [Abstract][Full Text] [Related]
18. Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. De Luca L; Steg PG; Bhatt DL; Capodanno D; Angiolillo DJ J Am Heart Assoc; 2021 Jul; 10(13):e022125. PubMed ID: 34212768 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. O'Donoghue ML; Bhatt DL; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Liu T; Deliargyris EN; Mahaffey KW; White HD; Harrington RA; Circulation; 2016 Jan; 133(3):248-55. PubMed ID: 26762525 [TBL] [Abstract][Full Text] [Related]
20. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]